

Bangkok Dusit Medical Services (BDMS)

Analyst Presentation 2Q21 & 6M21 Results

13 August 2021

Important Notice

- The information contained in this presentation is for information purposes only and does not constitute an offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for share in Bangkok Dusit Medical Services Public Company Limited ("BDMS" and shares in BDMS, "shares") in any jurisdiction nor should it or any part of it from the basis of, or be relied upon in any connection with, any contract or commitment whatsoever.
- This presentation may include information which is forward-looking in nature. Forward-looking information involve known and unknown risks, uncertainties and other factors which may impact on the actual outcomes, including economic conditions in the markets in which BDMS operates and general achievement of BDMS business forecasts, which will cause the actual results, performance or achievements of BDMS to differ, perhaps materially, from the results, performance or achievements expressed or implied in this presentation.
- This presentation has been prepared by the BDMS. The information in this presentation has not been independently verified. No representation, warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions in this presentation. None of the BDMS or any of its agents or advisors or any of their respective affiliates, advisors or representatives, shall have any liability (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation.
- This presentation is made, furnished and distributed for information purposes only. No part of this presentation shall be relied upon directly or indirectly for any investment decision-making or for any other purposes.
- This presentation and all other information, materials or documents provided in connection therewith, shall not, either in whole or in part, be reproduced, redistributed or made available to any other person, save in strict compliance with all applicable laws.

Contents

- 2Q21 & 6M21 Financial Summary
- Highlights & Update
- Operational Statistics
- Financial Performance

2Q21 & 6M21 Financial Summary



2Q21 Operational Recap and Financial Summary





2Q21 Highlights

	2Q21	
	% Chg	% to
		Revenue
Operating income	24%	
	THB 17,397 mm	
Patient revenue	26%	
	THB 16,443 mm	
Breakdown by nationality		
Thai	27%	82%
International	24%	18%
Breakdown by location		
Bangkok & Vicinity	27%	58%
 Outside Bangkok 	20%	42%
Breakdown by type of patie	ents	
Outpatients	22%	44%
Inpatients	30%	56%

Remark: - Operating income is calculated from hospital revenue + revenue from sales of goods + other income

- All operational statistics are from BDMS management report

Profitability and Ratio

(THB mm)	2Q21	2Q20	Chg. (yoy)
EBITDA	3,681	2,587	42%
EBITDA margin	21.2%	18.5%	
EBIT	2,139	972	120%
EBIT margin	12.3%	7.0%	
Net profit	1,452	458	217%
Net profit margin	8.3%	3.3%	

Remark: - Margin was calculated as a percentage of operating income

Commentary

- Patient revenue grew 26% yoy mainly from
 - Higher revenue from COVID-19 testing and treatment.
 If excluding COVID-19 related revenue, patient revenue would increase approximately 12% yoy
 - Higher volume growth from both Thai and International (mostly from expatriates) together with growth from health insurance and domestic contract patients

6M21 Operational Recap and Financial Summary



6M21 Highlights

	6M21	
	% Chg	% to
		Revenue
Operating income	(1)%	
	THB 33,678 mm	
Patient revenue	(1)%	
	THB 31,754 mm	
Breakdown by nationality		
Thai	8%	82%
International	(27)%	18%
Breakdown by location		
Bangkok & Vicinity	1%	57%
Outside Bangkok	(4)%	43%
Breakdown by type of patie	ents	
Outpatients	3%	46%
Inpatients	(2)%	54%


Profitability and Ratio

(THB mm)	6M21	6M20	Chg. (yoy)
EBITDA	7,208	7,377	(2)%
EBITDA margin	21.4%	21.7%	
Share of profit from associates	8	181	(96)%
EBIT	4,102	4,398	(7)%
EBIT margin	12.2%	12.9%	
Net profit	2,791	3,026	(8)%
Net profit margin	8.3%	8.9%	

Commentary

 Net profit decreased 8% yoy mainly from a decrease in share of profit from associates as a results of divestment of all investment in Bumrungrad Hospital Public Co., Ltd. (BH) during 4Q20

Highlights & Update



BDMS Response to COVID-19



Caring for our Patients, Doctors, Nurses, Employee and the Communities

Our Frontline Team



11,000+
doctors

8,000+

Registered
nurses



8,600*
tests per day



100* beds

Vaccination

Testing

Hospitel

Field Hospital

Cohort Wards

1 million+



* Capacity

4,200+*



2,850+ beds



COVID-19: Examples of Our Vaccination Initiatives



Supporting Vaccination Roll-out









Bangkok Hospital together with Siam Paragon, Bangkok
 Metropolitan Administration and Thai Chamber of
 Commerce roll-out COVID-19 vaccination for the public
 starting since 7 Jun 2021 at Siam Paragon's Convention
 Center Royal Paragon Hall

















COVID-19: Examples of Our Vaccination Initiatives



Supporting Vaccination Roll-out





 Phyathai and Paolo Hospital Group together with Siam Commercial Bank (SCB), Bangkok Metropolitan Administration and Thai Chamber of Commerce roll-out vaccination at SCB Head Office





 Samitivej Sukhumvit and Samitivej Srinakarin Hospital together with Emporium, Bangkok Metropolitan Authority and Sport Authority of Thailand roll-out vaccination at Emporium



 8 BDMS network hospitals provided vaccination services for French citizens aged 55 or older residing in Thailand







 Bangkok Pattaya provided vaccination services for Chinese citizens in Thailand

COVID-19: Examples of Our Vaccination Initiatives

Bangkok Dusit Medical Services

Supporting Vaccination Roll-out



Bangkok Siriroj together with Central Pattana and Phuket
 Public Health Department roll-out vaccination at Central
 Phuket to support government Phuket Sandbox strategy





Bangkok Rayong helps roll-out vaccination



BDMS has administered


1 million+
Doses

of COVID-19 vaccines nationwide

COVID-19: Testing Volume Trend




Increasing COVID-19 Testing Capacity from 6,880 tests/day during beginning of 3rd wave to now 8,600 tests/day



^{*} COVID-19 testing included PCR, Rapid Antibody and Rapid Antigen





- In July 2021, testing volume peaked at ~ 9,000 tests / day
- Upcountry volume increased mainly from Southern area due to Phuket Sandbox

COVID-19: Hospitel



Increasing Hospitel Rooms for Treating COVID-19 patients with Mild Symptoms

EXAMPLE of HOSPITELS















Remark: Data as of 7 Aug 2021

COVID-19: BDMS Field Hospital



A 100-bed Field Hospital to Take Care of COVID-19 patients with Moderate Symptoms



















- BDMS teams up with The Royal Thai Air Force and our corporate partners to set up 100-bed field hospital for COVID-19 patients with moderate symptoms (yellow) at *Thupatemi Stadium* to help take the pressure off hospitals struggling to cope with more seriously ill patients
- BDMS uses 5 intelligent robots to deliver food and medicine to reduce transmission risk while health workers will monitor patients thru VDO link


COVID-19: Cohort Wards



Increasing Cohort Wards for Treating COVID-19 Patients with Moderate and Serious Symptoms







- Cohort wards increased from 1,900 beds as of June
 2021 to 2,852 beds as of July 2021 (~ 46% of total 6,268 available beds)
- Occupancy rate of cohort wards increased from ~75% in April-May to 90% in Jun and reached 95% in July 2021

Viriyah & BDMS New Exclusive Health Insurance: Cancer Pro by BDMS





ตารางผลประโยชน์ความคุ้มครองประกันภัย โรคมะเร็งและอุบัติเหตุพิเศษ

เลเปละโยชน์ดองนอันอออจ		ผลประโยชน์ (บาท)			
ผลประโยชน์ความคุ้มครอง	ιιωu 1	IIWU 2	IIWU 3		
ค่ารักษาพยาบาลโรคมะเร็งสูงสุดต่อปี	3,000,000	6,000,000	9,000,000		
ค่าห้อง และค่าอาหาร ค่าบริการในโรงพยาบาล (ผู้ป่วยใน)					
• ค่าห้องผู้ป่วยปกติ(สูงสุดไม่เทิน 365 วัน)	8,000 10,000 12,000				
 ๑ ค่าห้องผู้ป่วยหนัก (สูงสุดใม่เกิน 15 วัน) 	16,000	20,000	24,000		
ค่ารักษาพยาบาลและค่าบริการทั่วไป					
♦ คีโม ฉายแสง					
• ค่าผ่าตัด					
๑ ค่ายาผู้ป่วยกลับบ้าน	จ่ายตามจริง*				
♦ การรักษาแบบเฉพาะเจาะจงต่อเชลล์มะเร็ง (Targeted Therapy)					
ค่าธรรมเนียมแพทย์					
ค่าธรรมเนียมแพทย์ผ่าตัด สำหรับแพทย์หรือคณะแพทย์ ผู้ช่วยศัลยแพทย์ หรือแพทย์ที่ทำการผ่าตัดหรือหัตกการทางการแพทย์					
 ค่าธรรมเนียมแพทย์วิสัญญี / พยาบาลวิสัญญี 		จ่ายตามจริง*			
 คำแพทย์เยี่ยมใช้ หรือค่าปรึกษาแพทย์ผู้เชี่ยวชาญเฉพาะโรค 	-				
ผลประโยชน์การประกันภัยอุบัติเหตุส่วนบุคคล					
 การเสียชีวิต หรือสูญเสียอวัยวะ สายตา หรือทุพพลภาพกาวรสิ้นเชิงจาก อุบัติเหตุ 	50,000	50,000	50,000		

Viriyah & BDMS New Exclusive Health Insurance: Cancer Pro by BDMS




ประเภทการตรวจ		ช่วงอายุ(ปี)					
		-40	41	-50	51	ขึ้นไป	
		Ŋ	ช	Ŋ	ß	Ŋ	
Complete Blood Count ดูความสมบูรณ์ของเม็ดเลือด	Å	*	*	x	*	Â	
Glucose ตรวจเบาหวาน	Â	Å	2	Å	2	Â	
Cholesterol ไขมันในเลือด	*	2	*	*	*	Â	
LDL- Cholesterol (direct)	*	Â	2	*	2	â	
HDL- Cholesterol	*	*	2	*	2	Ŕ	
Creatinine (plus GFR) ตรวจการทำงานของใต	*	2	2	2	*	â	
Blood Urea Nitrogen ตรวจการทำงานของใต	Â	â	*	*	2	Â	
Bilirubin ตรวจการทำงานของถุงน้ำดี	2	*	*	*	2	Å	
ALT (SGPT) ตรวจการทำงานของตับ	2	2	Â	8	2	*	
AST (SGOT) ตรวจการทำงานของตับ	*	2	Â	*	2	*	
Triglycerides ไขมันในเลือด	2	2	2	×	Å	*	
Urine Examination ตรวจปีสสาวะ ดูการติดเชื้อ น้ำตาล	*	2	Â	8	2	*	
Chest X-ray ตรวจการทำงานของปอด	â	2	Å	2	â	*	
CEA ตรวจมะเร็งลำใส้ ดูระดับของสารก่อมะเร็ง	*	*	2	*	Â	*	
PSA ตรวจมะเร็งต่อมลูกหมาก					Â		
Occult blood (Fecal Immunochemical test) ตรวจมะเร็งลำไส้					â	â	
Pap smear ตรวจมะเร็งปากมดลูก		Å		*		â	
Ultrasound Whole Abdomen ตรวจมะเร็งในช่องท้อง			*	2	Â	Â	
Mammograms with Ultrasound Breast Both-Sides ตรวจมะเร็งเต้านม อายุ 41 – 55 ปี ตรวจทุกปี อายุ 56 ปี ขึ้นไป ตรวจทุก 2 ปี				Å		â	

ตารางเบี้ยประกันภัยสำหรับรายบุคคล

ช่วงอายุ (ปี)	เบี้ยประกันภัยรายปี (รวมอากรแสตมป์)				
03001q (U)	IIωu 1	แผน 2	แผน 3		
21-25	6,240	6,600	6,960		
26–30	7,200	7,680	8,160		
31-35	9,120	9,840	10,440		
36-40	12,120	12,960	13,920		
41-45	22,680	24,120	25,680		
46–50	27,480	29,400	31,440		
51-55	32,280	34,800	37,320		
56-60	39,480	42,840	46,200		



BDMS was the Only Thai Listed Company that was Awarded as "Most Honored Company" from Institutional Investor





BDMS ranked No. 1 in all 5 categories namely Best
 CEO, Best CFO, Best IR Professional, Best IR Program
 and Best ESG in Healthcare & Pharmaceuticals for
 the rest of Asia (ex-China)







Operational Statistics




Operating Income Growth




Quarterly Operating Income Trend

(THB mm)

Growth YoY



Monthly Patient Revenue Trend



Commentary


2Q21 Operating income grew 24% yoy mainly from

YoY

- Patient revenue grew 26% yoy due to higher COVID-19 related services revenue, higher patient volume and higher revenue growth from health insurance & domestic contract patients
- If excluding revenue from COVID-19 related services, patient revenue grew 12% yoy
- **2Q21 Operating income grew 7% qoq mainly from**
 - Patient revenue grew 7% qoq driven by the 3rd wave of COVID-19 resulting in higher patient volume especially inpatients

Revenue breakdown in 2Q21

- COVID-19 revenue
- Non COVID-19 revenue




QoQ

Thai and International Patients




Revenue Contribution by Nationality



Top 5 Nationality contribution in 6M21





Commentary

- In 2Q21, Revenue from Thai patients grew 27% and interpatients grew 24% yoy
 - Growth of inter patient revenue was mainly from Japanese patients 37%, CLMV patients 26% and UK patients 20% yoy
- Revenue from Thai patients grew 9% and inter patients grew 4% qoq


- In 6M21, Revenue from Thai patients grew 8% while inter patients decreased by 27% yoy
 - Decrease in revenue from inter patients was mainly from decrease of Middle East patients 69%, Australia patients 44% and CLMV patients 31% yoy

YoY

Patient Mix




Revenue Contribution by Patient Types



- In 2Q21, OPD revenue increased 22% and IPD revenue increased 30% yoy
- In 6M21, OPD revenue increased 3% while IPD revenue decreased 2% yoy

6M21 Patient Revenue by Payor




In 6M21, Revenue portion from social security and UCEP increased mainly from COVID-19 treatment during 2Q21


Patient Volume and Occupancy Rate



Number of OPD Visits per Day



Average Daily Census (ADC)




Occupancy Rate Based on Available Beds



Average Length of Stay (days)




Financial Highlights




Diversified Sources of Revenues and Profitability



CoE Operating Income Contribution in 6M21



CoE Total EBITDA Contribution in 6M21




Commentary

- In 6M21, revenue from Center of Excellence (CoE) contributed 48% of operating income and 50% of total EBITDA
- Revenue from CoE decreased 4% yoy due mainly to decrease in inter patients. However, BCM and SVNH had revenue growth of 15% and 2% yoy, respectively in 6M21


^{*} SVNH included SVH and SNH performance

Profitability Trend










Core Profit & Core Profit Margin

(THB mm)




- In 2Q21, net profit was THB 1,452 million, increased by 217% yoy mainly from higher operating income, continued cost saving program together with higher finance income and lower finance expenses
- In 6M21, net profit was decreased by 8% yoy due mainly to no share of profit from BH due to divestment of all investment in BH during 4Q20

^{*} Excluding non-recurring items


Capital Management




Capital Structure as of June 2021




Gearing Ratios: Well Within Covenants



Dividend Payment & Payout Ratio



Interest Coverage



Appendix



For More Information:- www.bangkokhospital.com

Group 1 (Bangkok&West&Cambodia)	<u>Ownership</u>	No. of Beds	Group 4 (North&Northeast)	<u>Ownership</u>
 Bangkok Hospital 	100%]	373	26. Bangkok Chiangmai (BCM)	100% 🥝
2. Bangkok Heart Hospital	100%	97	27. Bangkok Ratchasima (BKH)	91.4%
3. Wattanosoth Hospital - (BHQ)	100% - 🥝	48	28. Bangkok Pakchong (BHP)	91.4%
4. Chiva Transitional Care	100%	52	29. Bangkok Udon (BUD)	100%
5. Bangkok International	100%]	172	30. Bangkok Phitsanulok (BPL)	100%
6. Bangkok Huahin (BHN)	100% 🥝	64	31. Bangkok Khon Kaen (BKN)	100%
7. Bangkok Sanamchan (BSN)	100%	210	32. Bangkok Chiangrai (BCR)	100%
8. Thepakorn (TPK)	50.0%	100		
9. Bangkok Phetchaburi (BPR)	100%	255	Group 5	
10. Bangkok Muangraj (BMR)	100%	142	33. Phyathai 1 (PT1)	98.6%
11. Royal Phnom Penh (RPH)	100% 🥝	100	34. Phyathai 2 (PT2)	97.8%
12. Royal Angkor International (RAH)	80.0%	30	35. Phyathai 3 (PT3)	97.6%
			36. Phyathai Sriracha (PTS)	74.2%
Group 2			37. Phyathai Nawamin (PTN)	99.8%
13. Samitivej Sukhumvit (SVH)	95.8%	311	38. Paolo Paholyothin (PLP)	100%
14. Samitivej Srinakarin (SNH)	95.8%	400	39. Paolo Samutprakarn(PLS)	93.7%
15. Samitivej Sriracha (SSH)	70.1%		40. Paolo Chokchai 4 (PLC)	85.7%
16. Samitivej Thonburi (STH)	64.0%	150	41. Paolo Rangsit (PLR)	100%
17. Samitivej Chonburi (SCH)	100%	260	42. Paolo Kaset (PLK)	100%
18. Samitivej Chinatown (SCT)	100%	59	43. Paolo Phrapradaeng (PLD)	84.0%
19. BNH Hospital (BNH)	91.5%	144	43. Table Finaplaceing (FED)	04.070
Group 3 (East)				
20. Bangkok Pattaya (BPH)	97.3%	400		
21. Bangkok Rayong (BRH)	100% 🥝	220		
22. Bangkok Chanthaburi (BCH)	99.7%	185		
23. Bangkok Trat (BTH)	99.8%	114		
24. Sri Rayong (SRH)	100%	195		
25. Jomtien (JTH)	100%	232		

No. of Beds		Gro	up 6 (South)	Ow	vnership	No.	of Be	d
0	175	44.	Bangkok Phuket (BPK)		99.7% (0	266	
	171	45.	Bangkok Siriroj (BSI)		100%	0	151	
	40	46.	Dibuk (DBK)		99.7%		100	
	120	47.	Bangkok Hat Yai (BHH)		98.8%		200	
	195	48.	Bangkok Samui (BSH)		100%		52	
	140	49.	Bangkok Surat (BSR)		100%		150	

Group 7: Non-Hospital

1.	National Healthcare System	100%
2.	Bio Molecular Laboratories	95.0%
3.	The Medicpharma	87.1%
4.	A.N.B Laboratories	100%
5.	Save Drug Center (SDC)	100%
6.	General Hospital Products	47.0%

BDMS Wellness

1.	BDMS Wellness Clinic	100%
2.	BDMS Wellness Resort	100%
	(Mövenpick BDMS Wellness Reso	rt)

Remark:- Number of beds is structured beds